Bio-Techne (NASDAQ:TECH) Trading Up 7% on Earnings Beat

Shares of Bio-Techne Corp (NASDAQ:TECH) were up 7% during trading on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $69.92 and last traded at $69.16. Approximately 2,958,199 shares traded hands during trading, an increase of 21% from the average daily volume of 2,450,796 shares. The stock had previously closed at $64.63.

The biotechnology company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.43 by $0.03. The company had revenue of $295.88 million for the quarter, compared to analyst estimates of $290.20 million. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.Bio-Techne’s quarterly revenue was down .4% compared to the same quarter last year. During the same period last year, the company earned $0.42 earnings per share.

Bio-Techne Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 27th. Shareholders of record on Monday, February 16th will be issued a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 13th. Bio-Techne’s dividend payout ratio (DPR) is presently 65.31%.

Key Stories Impacting Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Q2 results beat analysts: adjusted EPS of $0.46 topped estimates and revenue of ~$296M beat consensus; operating margin improved materially (~244 bps). This supports near‑term profitability momentum. Reuters: Bio-Techne beats quarterly estimates
• Positive Sentiment: Company outlook: management signaled mid‑single‑digit underlying growth for fiscal 2026 with margin expansion and “cell therapy normalization” ahead — a constructive forward signal for revenue recovery and margin leverage. MSN: Guidance and outlook
• Positive Sentiment: Dividend declared: Board approved a $0.08 quarterly dividend (payable Feb. 27) — modest but signals capital return discipline. PR Newswire: Dividend announcement
• Positive Sentiment: Analyst moves: Evercore raised its price target from $62 to $68 (in‑line rating), and Citi reiterated a Buy with an $80 target — mixed but includes higher targets that could support upside. Benzinga: Evercore note
• Neutral Sentiment: Conference call / transcripts available — contains management commentary that investors will parse for cadence on cell‑therapy recovery and margin timing. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Industry developments referenced in roundups (new ECM tech, lab M&A) could be relevant longer term but are not immediate drivers of TECH’s stock. BioTechniques: industry bi‑weekly
• Negative Sentiment: Top‑line softness: reported revenue was roughly flat organically and down ~0.4% YoY — investors disappointed by lack of stronger growth despite the beat. PR Newswire: Q2 results release
• Negative Sentiment: Valuation and expectations: TECH trades at a high P/E and elevated PEG, which increases sensitivity to any growth disappointments and may pressure the stock despite margin gains.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Deutsche Bank Aktiengesellschaft set a $72.00 price objective on Bio-Techne and gave the stock a “buy” rating in a research note on Friday, December 12th. Zacks Research downgraded Bio-Techne from a “hold” rating to a “strong sell” rating in a research note on Wednesday, December 17th. Benchmark reaffirmed a “buy” rating on shares of Bio-Techne in a research note on Tuesday. Stifel Nicolaus set a $65.00 target price on shares of Bio-Techne and gave the stock a “hold” rating in a report on Thursday. Finally, Argus increased their target price on shares of Bio-Techne from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Thursday, November 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Bio-Techne currently has an average rating of “Moderate Buy” and an average price target of $72.31.

Hedge Funds Weigh In On Bio-Techne

Several institutional investors and hedge funds have recently bought and sold shares of TECH. Goldman Sachs Group Inc. raised its position in shares of Bio-Techne by 12.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,063,939 shares of the biotechnology company’s stock valued at $62,379,000 after buying an additional 113,634 shares during the period. Woodline Partners LP increased its stake in Bio-Techne by 40.0% during the first quarter. Woodline Partners LP now owns 13,356 shares of the biotechnology company’s stock worth $783,000 after acquiring an additional 3,814 shares during the last quarter. Truist Financial Corp lifted its stake in shares of Bio-Techne by 20.9% in the 2nd quarter. Truist Financial Corp now owns 17,671 shares of the biotechnology company’s stock valued at $909,000 after purchasing an additional 3,060 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Bio-Techne by 5.2% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,646 shares of the biotechnology company’s stock worth $1,062,000 after purchasing an additional 1,016 shares during the period. Finally, Valeo Financial Advisors LLC purchased a new position in shares of Bio-Techne during the 2nd quarter worth $210,000. 98.95% of the stock is currently owned by institutional investors and hedge funds.

Bio-Techne Stock Down 4.1%

The stock has a market capitalization of $10.26 billion, a price-to-earnings ratio of 129.14, a P/E/G ratio of 4.74 and a beta of 1.48. The business has a 50-day moving average of $63.25 and a 200-day moving average of $59.25. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.81 and a current ratio of 4.54.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.